Consensus statement on the use of Xelma in diabetic foot ulcers

Abstract

Diabetic foot ulcers are a common and costly complication of diabetes, often presenting in a chronic wound state. Adjuvant therapies may be used to kick-start the healing process in hard-to-heal and chronic wounds, but specific placement of these therapies in the care pathway is not always clear. A group of experienced clinicians developed the following consensus statement and treatment algorithm on the use of the extracellular matrix protein therapy Xelma (Mölnlycke Health Care, Dunstable) specifically in diabetic foot ulcers.